LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash
Condition: Colon or Rectal Cancer
Sponsor: Lutris Pharma Ltd.
Protocol L-02-01: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions.
Topical treatment for patients who experience acneiform rash after beginning anti-cancer treatment with a regimen including either cetuximab or panitumumab.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.